These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22460813)

  • 21. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
    Esgueva R; Perner S; J LaFargue C; Scheble V; Stephan C; Lein M; Fritzsche FR; Dietel M; Kristiansen G; Rubin MA
    Mod Pathol; 2010 Apr; 23(4):539-46. PubMed ID: 20118910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
    Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS
    Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
    Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
    Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
    Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
    PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
    Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERG rearrangement is present in a subset of transition zone prostatic tumors.
    Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
    Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deletion of 8p is an independent prognostic parameter in prostate cancer.
    Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
    Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
    Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis.
    Sathyanarayana UG; Birch C; Nagle RB; Tomlins SA; Palanisamy N; Zhang W; Hubbard A; Brunhoeber P; Wang Y; Tang L
    Appl Immunohistochem Mol Morphol; 2015; 23(5):364-73. PubMed ID: 25265431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
    Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
    PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.
    Lotan TL; Carvalho FL; Peskoe SB; Hicks JL; Good J; Fedor H; Humphreys E; Han M; Platz EA; Squire JA; De Marzo AM; Berman DM
    Mod Pathol; 2015 Jan; 28(1):128-137. PubMed ID: 24993522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
    Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
    Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
    Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
    PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.